Helixmith said it has signed a three-party memorandum of understanding with Cartexell and GI Cell for joint research on cell gene therapy products.

The trilateral MOU will encourage cooperation between the three companies to identify candidate materials for cell gene therapy and cooperate in manufacturing and commercializing clinical trial drugs.

Accordingly, the three companies will utilize Helixmith's Cell & Gene Therapy Center's technology and one-stop service for cell gene therapy development and production, Cartexell's CAR-T (Chimeric Antigen Receptor) cell therapy technology, and GI Cell's immune cell culture and freezing system.

"The company expects this MOU to show differentiated competitiveness in the cell gene therapy business," Helixmith CEO Yoo Seung-shin said. "In the future, we will leap forward as a global gene therapy company representing Korea in the global market through various agreements with excellent companies."

Cartexell CEO Seo Jae-hee also said, "Through the convergence of Heliximith and Cartexell's advanced CAR gene engineering and delivery technology with GI Cell's differentiated immune cell culture technology, we expect to secure a CAR-NK cell therapy pipeline early."